Champions Oncology posts record $59.4 million fiscal 2026 revenue

Champions Oncology reported financial results on July 27, 2026 for its fiscal year and fourth quarter ended April 30, 2026, announcing record annual revenue for fiscal 2026 alongside continued investment in radiopharmaceuticals, the data platform and its commercial organization.¹

CEO Robert Brainin said the company advanced several strategic initiatives during the year, including expanding its radiopharmaceutical platform, strengthening its data strategy, making progress toward commercial application of Corellia's technology, and growing its commercial organization.¹

Total oncology revenue for fiscal 2026 reached $59.4 million, a 4% increase compared to $56.9 million for fiscal year 2025.¹ That growth came despite the absence of approximately $4.5 million of data license revenue recognized in the prior fiscal year that did not recur in fiscal 2026, with the increase driven by continued strength in the company's core research services business.¹

For the fourth quarter, revenue was $13.8 million, compared to $12.4 million for the same period last year, an increase of 12%.¹ Adjusted EBITDA for the quarter was $158,000, compared to an adjusted EBITDA loss of $1.2 million in the prior year period.¹ CFO David Miller said the company delivered record annual revenue despite the absence of the prior year's significant data licensing transaction and generated positive Adjusted EBITDA in each quarter of the fiscal year.¹

On cash position, the company ended the quarter with a cash position of $4.9 million and no debt.¹ Full fiscal 2026 results will be detailed in the company's Form 10-K, available no later than Wednesday, July 29, 2026.¹ A conference call to discuss the results was scheduled for 4:30 p.m. ET (1:30 p.m. PT) on July 27, 2026.¹